MedTrace Logo

Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

NCT02656797 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-03-15

No results posted yet for this study

Summary

Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica.

Conditions

  • Leishmaniasis

Interventions

DRUG

Topical Amphotericin-B 0.4% liposomal gel

Topical Amphotericin-B 0.4% liposomal gel

Sponsors & Collaborators

  • Soroka University Medical Center

    lead OTHER

Principal Investigators

  • Amir Horev, MD · Soroka University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2021-06-01
Completion
2021-10-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656797 on ClinicalTrials.gov